Greenberg, P. L. (2000). Myelodysplastic syndrome. In Hematology: Basic Principles and Practice, 3rd edn, ed. , R. Hoffman, , E. J. Benz, , S. J. Shattil, , B. Furieet al.New York: Churchill Livingstone, pp. 1106–29Google Scholar

Sanz, G. F., Sanz, M. A., Vallespì, T.et al. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395–408Google Scholar

Bennett, J. M., Catovsky, D., Daniel, M. T.et al. (1982). Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 51, 189–99CrossRefGoogle ScholarPubMed

Vardiman, J. W., Harris, N. L., and Brunning, R. D. (2002). The World Health Organization (WHO) classification of the myeloid neoplasms (review). Blood, 100, 2292–302CrossRefGoogle Scholar

Greenberg, P., Cox, C., Beau, M. M.et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079–88. (published erratum appears in Blood, 1998; 91, 1100)Google ScholarPubMed

Appelbaum, F. R. and Anderson, J. (1998). Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 12 (Suppl. 1), S25–9Google ScholarPubMed

Nevill, T. J., Fung, H. C., Shepherd, J. D.et al. (1998). Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood, 92, 1910–17Google ScholarPubMed

Castro-Malaspina, H., Harris, R. E., Gajewski, J.et al. (2002). Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood, 99, 1943–51CrossRefGoogle ScholarPubMed

Cutler, C., Lee, S., Greenberg, P.et al. (2002). A decision analysis of allogeneic stem cell transplantation for MDS: delayed transplantation for low risk MDS is associated with improved outcome. Blood, 100 (Part 1), 74a (abstract 270)Google Scholar

Witte, T., Suciu, S., Verhoef, G.et al. (2001). Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood, 98, 2326–31CrossRefGoogle ScholarPubMed

Yakoub-Agha, I., Salmonière, P., Ribaud, P.et al. (2000). Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J. Clin. Oncol., 18, 963–71CrossRefGoogle Scholar

Scott, B. L., Deeg, H. J., and Appelbaum, F. R. (2003). Pre-transplant induction chemotherapy and post-transplant relapse in patients with advanced MDS. Blood, 102 (Part 1), 152a. (abstract 523)Google Scholar

Runde, V., Witte, T., Arnold, R.et al. (1998). Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant., 21, 255–61CrossRefGoogle ScholarPubMed

O'Donnell, M. R., Long, G. D., Parker, P. M.et al. (1995). Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J. Clin. Oncol., 13, 2973–9CrossRefGoogle ScholarPubMed

Ratanatharathorn, V., Karanes, C., Uberti, J.et al. (1993). Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood, 81, 2194–9Google ScholarPubMed

Deeg, H. J., Storer, B., Slattery, J. T.et al. (2002). Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood, 100, 1201–7CrossRefGoogle ScholarPubMed

Guardiola, P., Runde, V., Bacigalupo, A.et al. (2002). Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood, 99, 4370–8CrossRefGoogle ScholarPubMed

Sierra, J., Pérez, W. S., Rozman, C.et al. (2002). Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood, 100, 1997–2004Google ScholarPubMed

Appelbaum, F. R., Barrall, J., Storb, R.et al. (1990). Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann. Intern. Med., 112, 590–7CrossRefGoogle ScholarPubMed

Anderson, J. E., Appelbaum, F. R., Schoch, G.et al. (1996). Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J. Clin. Oncol., 14, 220–6CrossRefGoogle ScholarPubMed

Arnold, R., Witte, T., Biezen, A.et al. (1998). Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant., 21, 1213–16CrossRefGoogle ScholarPubMed

Jurado, M., Deeg, H. J., Storer, B.et al. (2002). Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol. Blood Marrow Transplant., 8, 161–9CrossRefGoogle ScholarPubMed

Bornhäuser, M., Storer, B., Slattery, J. T.et al. (2003). Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood, 102, 820–6CrossRefGoogle ScholarPubMed

Carella, A. M., Champlin, R., Slavin, S., McSweeney, P. and Storb, R. (2000). Mini-allografts: ongoing trials in humans (editorial). Bone Marrow Transplant., 25, 345–50CrossRefGoogle Scholar

McSweeney, P. A. and Storb, R. (1999). Mixed chimerism: preclinical studies and clinical applications (review). Biol. Blood Marrow Transplant., 5, 192–203CrossRefGoogle Scholar

Storb, R., McSweeney, P. A., Sandmaier, B. M.et al. (2000). Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the 21st century. Transplant Proc., 32, 2548–9CrossRefGoogle Scholar

Kroger, N., Schetelig, J., Zabelina, T.et al. (2001). A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant., 28, 643–7CrossRefGoogle ScholarPubMed

Stuart, M. J., Cao, T. M., Sandmaier, B. M.et al. (2003). Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). Blood, 102 (Part 1), 185a (abstract 644)Google Scholar

Parker, J. E., Shafi, T., Pagliuca, A.et al. (2002). Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br. J. Haematol., 119, 144–54CrossRefGoogle ScholarPubMed

Taussig, D. C., Davies, A. J., Cavenagh, J. D.et al. (2003). Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J. Clin. Oncol., 21, 3060–5CrossRefGoogle ScholarPubMed

Kroger, N., Bornhauser, M., Ehninger, G.et al. (2003). Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann. Hematol., 82, 336–42CrossRefGoogle ScholarPubMed

Martino, R., Biezen, A., Iacobelli, S.et al. (2003). Reduced-intensity conditioning (RIC) for allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings in adults with myelodysplastic syndromes (MDS): a comparison with standard myeloablative conditioning: a study of the EBMT-Chronic Leukemia Working Party (EBMT-CLWP). Blood, 102 (Part 1), 184a (abstract 642)Google Scholar

Witte, T., Biezen, A., Hermans, J.et al. (1997). Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood, 90, 3853–7Google ScholarPubMed

Wattel, E., Solary, E., Leleu, X.et al. (1999). A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia, 13, 524–9CrossRefGoogle ScholarPubMed

Oosterveld, M., Suciu, S., Verhoef, G.et al. (2003). The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia, 17, 859–68CrossRefGoogle Scholar

Deeg, H. J., Shulman, H. M., Anderson, J. E.et al. (2000). Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood, 95, 1188–94Google ScholarPubMed

Sasaki, H., Manabe, A., Kojima, S.et al. (2001). Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia, 15, 1713–20CrossRefGoogle ScholarPubMed

Hasle, H., Wadsworth, L. D., Massing, B. G., McBride, M., and Schultz, K. R. (1999). A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br. J. Haematol., 106, 1027–32CrossRefGoogle ScholarPubMed

Novitzky, N. (2000). Myelodysplastic syndromes in children. A critical review of the clinical manifestations and management. Am. J. Hematol., 63, 212–223.0.CO;2-D>CrossRefGoogle ScholarPubMed

Locatelli, F., Zecca, M., Niemeyer, C.et al. (1996). Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOG-MDS) and the Austria–Germany–Italy (AGI) Bone Marrow Transplantation Registry (review). Bone Marrow Transplant., 18 (suppl. 2), 63–8Google ScholarPubMed

Hasle, H., Arico, M., Basso, G.et al. (1999). Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia, 13, 376–85CrossRefGoogle ScholarPubMed

Woods, W. G., Barnard, D. R., Alonzo, T. A.et al. (2002). Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J. Clin. Oncol., 20, 434–40Google ScholarPubMed

Nagatoshi, Y., Okamura, J., Ikuno, Y., Akamatsu, M., and Tasaka, H. (1997). Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children. Int. J. Hematol., 65, 269–75CrossRefGoogle ScholarPubMed

Davies, S. M., Wagner, J. E., DeFor, T.et al. (1997). Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br. J. Haematol., 96, 749–56CrossRefGoogle ScholarPubMed

Casper, J., Camitta, B., Truitt, R.et al. (1995). Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood, 85, 2354–63Google ScholarPubMed

Woolfrey, A. E., Gooley, T. A., Sievers, E. L.et al. (1998). Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood, 92, 3546–56Google ScholarPubMed

Locatelli, F., Noellke, P., Zecca, M.et al. (2003). Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS trial. Blood, 102 (Part 1), 186a (abstract 647)Google Scholar

Niemeyer, C. M., Arico, M., Basso, G.et al. (1997). Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood, 89, 3534–43Google ScholarPubMed

Sobecks, R. M., Beau, M. M., Anastasi, J., and Williams, S. F. (1999). Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant., 23, 1161–5CrossRefGoogle ScholarPubMed

Friedberg, J. W., Neuberg, D., Stone, R. M.et al. (1999). Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol., 17, 3128–35CrossRefGoogle ScholarPubMed

Micallef, I. N. M., Lillington, D. M., Apostolidis, J.et al. (2000). Therapy-related myelodsyplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J. Clin. Oncol., 18, 947–55CrossRefGoogle Scholar

Witte, T. (1999). Stem cell transplantation in myelodysplastic syndromes (review). Forum, 9, 75–81Google Scholar

Witherspoon, R. P., Deeg, H. J., Storer, B.et al. (2001). Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J. Clin. Oncol., 19, 2134–41CrossRefGoogle ScholarPubMed

Ballen, K. K., Gilliland, D. G., Guinan, E. C.et al. (1997). Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant., 20, 737–43CrossRefGoogle ScholarPubMed

Leahey, A. M., Friedman, D. L., and Bunin, N. J. (1999). Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant., 23, 21–5CrossRefGoogle ScholarPubMed

Castagna, L., El Weshi, A., Bourhis, J. H.et al. (1998). Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT) (letter). Br. J. Haematol., 103, 284–5CrossRefGoogle Scholar

Bader, P., Klingebiel, T., Schaudt, A.et al. (1999). Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia, 13, 2079–86CrossRefGoogle ScholarPubMed

Shiobara, S., Nakao, S., Ueda, M.et al. (2000). Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant., 26, 769–74CrossRefGoogle ScholarPubMed

Benesch, M., Wells, D. A., Leisenring, W.et al. (2002). Prognostic significance of pretransplant multidimensional flow cytometric parameters for posttransplant survival and relapse in 111 patients with myelodysplastic syndrome (MDS). Blood, 100 (Part 1), 97a (abstract 358)Google Scholar